Clinical Trial Update: A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD ) [Phase 1, Phase 2]

View source ↗

Summary

Prime Medicine is conducting a Phase 1/2 study to evaluate the safety and efficacy of PM359, a prime editing therapy, in participants with p47phox autosomal rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Granulomatous Disease

Drugs mentioned

• PM359

Snippet

Sponsor: Prime Medicine, Inc. | Conditions: Chronic Granulomatous Disease, Granulomatous Disease, Chronic | Phase 1, Phase 2 | Status: ENROLLING_BY_INVITATION